TLTobias J. Lange

Tobias J. Lange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tobias J. Lange has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hemodynamic effects of cycle ergometry and low-intensity handgrip in patients with pulmonary hypertension

    by Alexander Rueß, Stefan Stadler, Tobias Stark, Eugen Berezucki, Tobias J. Lange

    Introduction: In pulmonary hypertension (PH), the hemodynamic response to exercise during right heart catheterization (RHC) can unmask latent left heart disease, is associated with prognosis, and can facilitate the understanding of patient’s symptoms and the pathophysiology of heart failure. As cycle ergometry isn’t widely available, we compared the hemodynamic effects of ergometry with isometric handgrip exercise. Methods: This prospective study included 50 consecutive patients (mean age 68 ± 12 years, 54% female) with suspected or confirmed PH who underwent RHC. In a semi-recumbent position, hemodynamic parameters were recorded at rest and during both randomized exercise modalities, each sustained for a mean of 6–7 min and separated by another resting phase. Cardiac output was determined by thermodilution. Handgrip pressure was set to 20% of maximal force, while cycle ergometry was performed at a constant work rate between 10 and 50 watts. Results: Both modalities induced significant changes of hemodynamic parameters compared to baseline, which were considerably smaller during handgrip. Mean pulmonary arterial pressure increased by 14 mmHg under cycling vs. 4 mmHg under handgrip ( p < 0.001), pulmonary artery wedge pressure (PAWP) by 5 mmHg vs. 2 mmHg ( p < 0.001), and cardiac output by 1.5 l/min vs. 0.2 l/min ( p < 0.001). In patients with PAWP ≤ 15 mmHg at rest, an increase > 25 mmHg occurred in two cases during cycle ergometry but in none during handgrip exercise. Discussion: Compared with cycle ergometry, low-intensity isometric handgrip exercise at 20% of maximal force produces significantly smaller alterations in hemodynamic parameters measured by RHC in PH patients, and thus is not suitable as an adequate substitute for the established exercise modality.


  • Open Access

    Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension

    by Natalie Bordag, Bence Miklos Nagy, Elmar Zügner, Helga Ludwig, Vasile Foris, Chandran Nagaraj, Valentina Biasin, Gabor Kovacs, Nikolaus Kneidinger, Ulrich Bodenhofer, et al.

    Rationale: Pulmonary hypertension (PH) poses a significant health threat. Current biomarkers for PH lack specificity and have poor prognostic capabilities. Objectives: To develop better biomarkers for PH that are useful for patient identification and management. Methods: An explorative analysis was conducted of a broad spectrum of metabolites in patients with PH, healthy control subjects, and diseased control subjects in training and validation cohorts, together with in vitro studies on human pulmonary arteries. Measurements and Main Results: High-resolution mass spectrometry was performed in 233 subjects coupled with machine learning analysis. Histologic and gene expression analysis was conducted, with a focus on lipid metabolism in human pulmonary arteries of idiopathic pulmonary arterial hypertension lungs and assessment of the acute effects of extrinsic fatty acids (FAs). We enrolled a training cohort of 74 patients with PH, 30 diseased control subjects without PH, and 65 healthy control subjects, as well as an independent validation cohort of 64 subjects. Among other metabolites, FAs were significantly increased. Machine learning showed a high diagnostic potential for PH. In addition, we developed fully explainable lipid ratios with exceptional diagnostic accuracy for PH (areas under the curve of 0.89 in the training cohort and 0.90 in the external validation cohort), outperforming machine learning results. These ratios were also prognostic and complemented established clinical markers and scores, significantly increasing their hazard ratios for mortality risk. Idiopathic pulmonary arterial hypertension lungs showed lipid accumulation and altered expression of lipid homeostasis–related genes. In human pulmonary artery smooth muscle and endothelial cells, FAs caused excessive proliferation and barrier dysfunction, respectively. Conclusions: Our metabolomics approach suggests that lipid alterations in PH provide diagnostic and prognostic information, complementing established markers. These alterations may reflect pathologic changes in the pulmonary arteries of patients with PH.


  • Open Access

    Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)

    by Tobias J. Lange, Pilar Escribano-Subias, Audrey Muller, Catarina C. Fernandes, Martina Fontana, Tatiana Remenova, Stefan Söderberg, Sean Gaine

    Introduction Risk assessment can aid management of pulmonary arterial hypertension (PAH) and clinical decision-making. This analysis describes characteristics, treatment patterns and outcomes of patients with PAH, categorised by risk status at time of treatment escalation with selexipag in clinical settings. Methods Patients initiating selexipag in the ongoing multicentre, prospective EXPOSURE (EUPAS19085) study were grouped as low, intermediate-low, intermediate-high or high risk of 1-year mortality according to the ESC/ERS 4-strata method. Results As of November 2022, 77% (535/698) of patients initiating selexipag had data allowing for risk calculation; 14% (N = 76) were low, 31% (N = 168) intermediate-low, 34% (N = 182) intermediate-high and 20% (N = 109) high risk of 1-year mortality. Overall, patients were predominantly female (71%), with idiopathic/heritable PAH (56%) or PAH associated with connective tissue disease (CTD-PAH; 27%), median age of 60 years and prevalent (2 years) disease. From low to high risk, proportion of CTD-PAH and age increased (from 12%–40% and 46–68 years, respectively); time from diagnosis decreased and presence of cardiovascular risk factors increased. Most patients across risk groups (74–81%) initiated selexipag as part of triple oral combination therapy. Overall median (Q1, Q3) selexipag exposure duration was 10.1 (3.5, 24.1) months. Proportions of hospitalised patients increased with increasing risk group (16–42% from low to high, respectively); more hospitalisations were PAH-related for the high risk (71%) versus other risk groups (47–54%). Kaplan–Meier survival estimates were 98%, 98%, 93% and 80% at 1-year and 98%, 92%, 81% and 67% at 2-years, from low to high risk, respectively. Conclusions In clinical settings, selexipag is initiated across all risk groups, predominantly as triple therapy. Only 45% of patients being at low/intermediate-low risk at selexipag initiation suggests an opportunity for more frequent patient monitoring and earlier treatment escalation, given that 4-strata risk assessment was prognostic for hospitalisations and survival in this contemporary PAH cohort. A graphical abstract is available with this article. Graphical Abstract


  • Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era

    by Felix Gerhardt, Eva Fiessler, Karen M. Olsson, Moritz Z. Kayser, Gabor Kovacs, Henning Gall, H. Ardeschir Ghofrani, Roza Badr Eslam, Irene M. Lang, Nicola Benjamin, et al.

    BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively. In accordance with current guidelines, acute vasoreactivity response was defined by a decrease of mean pulmonary artery pressure by ≥10 mm Hg to reach <40 mm Hg, without a decrease in cardiac output. Long-term response to CCBs was defined as alive with unchanged initial CCB therapy with or without other initial PAH therapy and World Health Organization functional class I/II and/or low European Society of Cardiology/European Respiratory Society risk status at 12 months after initiation of CCBs. Patients were followed for up to 5 years; clinical measures, outcome, and subsequent treatment patterns were captured. RESULTS: Of 3702 patients undergoing right heart catheterization for PAH diagnosis, 2051 had idiopathic, heritable, or drug-induced PAH, of whom 1904 (92.8%) underwent acute vasoreactivity testing. A total of 162 patients fulfilled acute vasoreactivity response criteria and received an initial CCB alone (n=123) or in combination with another PAH therapy (n=39). The median follow-up time was 60.0 months (interquartile range, 30.8–60.0), during which overall survival was 86.7%. At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn and/or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-term responders versus 73.0% in nonresponders. In addition to established vasodilator responder criteria, pulmonary artery compliance at acute vasoreactivity testing, low risk status and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at early follow-up correlated with long-term response and predicted survival. CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.


  • Open Access

    Intravenous Opioid Medication with Piritramide Reduces the Risk of Pneumothorax During CT-Guided Percutaneous Core Biopsy of the Lung

    by Andrea Goetz, Florian Poschenrieder, Frederike Georgine Steer, Florian Zeman, Tobias J. Lange, Sylvia Thurn, Barbara Greiner, Christian Stroszczynski, Wibke Uller, Okka Hamer, et al.

    Purpose: CT-guided percutaneous core biopsy of the lung is usually performed under local anesthesia, but can also be conducted under additional systemic opioid medication. The purpose of this retrospective study was to assess the effect of intravenous piritramide application on the pneumothorax rate and to identify risk factors for post-biopsy pneumothorax. Materials and Methods: One hundred and seventy-one core biopsies of the lung were included in this retrospective single center study. The incidence of pneumothorax and chest tube placement was evaluated. Patient-, procedure- and target-related variables were analyzed by univariate and multivariable logistic regression analysis. Results: The overall incidence of pneumothorax was 39.2% (67/171). The pneumothorax rate was 31.5% (29/92) in patients who received intravenous piritramide and 48.1% (38/79) in patients who did not receive piritramide. In multivariable logistic regression analysis periinterventional piritramide application proved to be the only independent factor to reduce the risk of pneumothorax (odds ratio 0.46, 95%-confidence interval 0.24, 0.88; p = 0.018). Two or more pleura passages (odds ratio 3.38, 95%-confidence interval: 1.15, 9.87; p = 0.026) and prone position of the patient (odds ratio 2.27, 95%-confidence interval: 1.04, 4.94; p = 0.039) were independent risk factors for a higher pneumothorax rate. Conclusion: Procedural opioid medication with piritramide proved to be a previously undisclosed factor decreasing the risk of pneumothorax associated with CT-guided percutaneous core biopsy of the lung. Level of Evidence 4: small study cohort. Graphic


  • Four-strata risk assessment in pulmonary arterial hypertension (PAH) patients treated with selexipag in real-world settings: Insights from EXPOSURE

    by Tobias Lange, Pilar Escribano, Audrey Muller, Martina Fontana, Stefan Soderberg, Sean Gaine

    EXPOSURE (EUPAS19085) is an ongoing observational study of PAH patients in Europe and Canada who initiate PAH-specific therapy. A risk assessment with 4-strata was introduced in the 2022 ESC/ERS PH guidelines to guide treatment decision at follow-up. This analysis presents characteristics, treatment patterns and outcomes of patients initiating selexipag between Sept 2017–Nov 2022, stratified by the 1-year mortality 4-strata ESC/ERS risk assessment (low, intermediate-low, intermediate-high and high strata). By 30th Nov 2022, 535/698 selexipag-treated patients had data allowing for risk score assessment at selexipag initiation (Table). 14% of patients were in the low risk stratum, 31% in the intermediate-low, 34% in the intermediate-high and 20% in the high. In this prevalent population, the majority (74–81%) received selexipag as part of triple combination therapy. During the exposure period, 47% (7/15;n=12) of all hospitalisations were PAH-related in low risk patients, 54% (37/69; n=39) in intermediate-low, 53% (58/109; n=62) in intermediate-high, and 71% (51/72; n=46) in high risk; death occurred in 1 (1%), 7 (4%), 22 (12%) and 23 (21%) in the 4 risk strata, respectively. Applying the recent ESC/ERS risk assessment indicated that in clinical practice, selexipag is initiated across all 4-risk strata, with about half of patients being at low or intermediate-low risk.

  • Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension

    by Tobias J. Lange

    The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for pulmonary hypertension have introduced a refined risk stratification to guide both initial and subsequent treatment of pulmonary arterial hypertension (PAH). The risk stratification at PAH diagnosis still comprises three risk categories (low, intermediate, high) and lists some new parameters. As the estimated 1‑year mortality is more than 20% in high-risk patients after diagnosis, an initial triple-combination therapy including parenteral prostacyclin analogues is recommended for this group. All other patients should receive a dual-combination therapy with an endothelin receptor antagonist and a phosphodiesterase‑5 inhibitor. However, this approach of initial combination therapy is only recommended for classic PAH, while monotherapy followed by regular follow-up and individualized therapy should be used for patients with cardiopulmonary comorbidities. For PAH patients without cardiopulmonary comorbidities, it is recommended to assess their risk at follow-up with a new 4‑strata classification, where the intermediate-risk group is split on the basis of three noninvasive parameters. Importantly, changes from intermediate–high to intermediate–low risk have been shown to be associated with a better prognosis. In addition, the recommendations on treatment escalation became more precise with the addition of a prostacyclin receptor agonist or switching a phosphodiesterase‑5 inhibitor to a soluble guanylate cyclase stimulator for intermediate–low risk and proceeding to triple-combination therapy with parenteral prostacyclin analogues already for intermediate–high risk. With sotatercept, the first non-vasodilator PAH treatment will become available in the near future to further enrich our treatment options for this chronic and still severe disease.


  • Open Access

    Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE

    by P Escribano, S Gaine, R Klement, A Muller, T J Lange, S Soderberg

    Background: Treatment patterns for patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) are currently not well described. Purpose: To use real-world data from the EXPOSURE study to describe clinical characteristics, treatment patterns and outcomes of PAH-CHD patients in current clinical practice. Methods: EXPOSURE (EUPAS19085) is an ongoing, multicentre, prospective, observational study of PAH patients initiating a PAH-specific therapy in Europe and Canada. Clinical characteristics, treatment patterns, hospitalisation and mortality are described for PAH-CHD patients classified into four clinical subgroups. Baseline was considered to be within 30 days of PAH-specific treatment initiation. Results: Between September 2017 and November 2021, there were 1588 PAH patients with follow-up data in EXPOSURE, of whom 168 (11%) had PAH-CHD. Of these, 40% (N=67) had Eisenmenger's Syndrome (ES), 25% (N=42) had PAH with coincidental CHD, 21% (N=35) had PAH with left-to-right shunts, and 14% (N=24) had PAH after CHD corrective surgery. Baseline characteristics are summarised in the Table. Across the subgroups, the median age was 46–53 years. Compared to the other subgroups, at baseline, ES patients had a substantially longer time from diagnosis (median [Q1, Q3]: 12.6 [3.3, 31.5] years), a lower 6MWD (median [Q1, Q3]: 400 [309, 480] m) and were more likely to be in WHO FC III/IV (Table). The majority of patients across all subgroups initiated a new PAH-specific therapy as part of combination therapy at enrolment (Table). Treatment patterns over time for ES patients are shown in the Figure. The majority of ES patients received double or triple combination therapy at baseline. Overall, most ES patients remained on the same treatment regimen 6 months after baseline, with limited treatment escalation (Figure). The median observation period ranged between 15.0 and 23.0 months for all subgroups (Table). Incidence of all-cause hospitalisation during this time was generally comparable across subgroups (Table). All-cause mortality incidence rates (95% CI) were higher in patients with ES (6.3 [2.3, 13.7]) and PAH after CHD corrective surgery (8.1 [1.7, 23.8]) compared to the other two subgroups (Table). Conclusions: In EXPOSURE, 11% of patients were PAH-CHD patients, with ES being the most common PAH-CHD aetiology. The majority of PAH-CHD patients were enrolled on combination therapy. ES patients had a longer time from diagnosis compared to other subgroups and their treatment patterns followed a stepwise approach. At 6 months post-baseline, the majority of ES patients were on double or triple combination therapy. Hospitalisation was comparable between subgroups and mortality was higher in ES and PAH after CHD corrective surgery patients. Funding Acknowledgement: Type of funding sources: Other. Main funding source(s): Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson